At the recent Fierce Pharma Forward event, our Chief Medical Officer and President of Global Product Development Richard Scranton MD MPH spoke on a panel about advances and challenges in developing long-acting drug delivery platforms. This clip from his panel discussion underscores the critical need for novel drug delivery options, like the LYNX® platform, for patient care and outcomes. If you missed the live event, you can still register to stream the event on demand and learn more about the future of drug delivery and the work we’re doing at Lyndra: https://lnkd.in/e4BFEJHv
Lyndra Therapeutics’ Post
More Relevant Posts
-
In partnership with Körber Pharma and Ypsomed AG Selfcare Solutions, we invite you to join us on 18th June 2024 at our free knowledge-sharing seminar in Basel, Switzerland, for insightful discussions around the key considerations and critical success factors of your injectable products’ lifecycle. Driven by considerations of time, cost, and internal resource limitations, sponsor companies often prioritize the immediate task at hand and achieving the next tangible milestone. Hear from Jerome Detreille, he will guide you through future considerations at each clinical phase to assist strategic planning to pave the way for long-term success, and you will learn: • The steps you need to prepare for in advance of progressing to the next clinical phase to accelerate timelines • Phase appropriate sterile drug product processing and analytical validation • Strategies for delivering positive patient health outcomes • The key elements of a commercial readiness checklist Seminar details and full agenda: https://lnkd.in/eae9YN5j #CDMO #BioTech #PatientCentricity #LetsTalkFuture
-
-
During the Clinical Trials Forum 2024 yesterday, our managing director Sabrina Suetens discussed various matters with Caroline Ven, CEO of pharma.be. Clinical trials are a crucial engine of innovation in healthcare. 🤝 In this context, it is important for the #pharma and #medtech sector to collaborate closely. Together, we can target therapies even more precisely, monitor the effects of treatments even more effectively, etc. 💗 In other words, by working together, we can create even greater impact for patients. #ClinicalTrialsForum #clinicaltrials #medicaltechnology #healthinnovation FAGG - Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten
-
-
Patient access is a critical challenge in the US pharma industry, impacting the pace of drug development and the delivery of life-saving treatments. To assess the current state of patient access, Norstella’s MMIT (Managed Markets Insight & Technology) surveyed over 300 industry professionals to uncover key trends and challenges. Watch this video to discover the survey’s key findings, and download the full MMIT Patient Access Report: https://ow.ly/I2iR50Tqrc1. #Pipeline2Patient #FollowNorstella
-
Patient access is a critical challenge in the US pharma industry, impacting the pace of drug development and the delivery of life-saving treatments. To assess the current state of patient access, Norstella’s MMIT (Managed Markets Insight & Technology) surveyed over 300 industry professionals to uncover key trends and challenges. Watch this video to discover the survey’s key findings, and download the full MMIT Patient Access Report: https://ow.ly/I2iR50Tqrc1. #Pipeline2Patient #FollowNorstella
-
Patient access is a critical challenge in the US pharma industry, impacting the pace of drug development and the delivery of life-saving treatments. To assess the current state of patient access, Norstella’s MMIT (Managed Markets Insight & Technology) surveyed over 300 industry professionals to uncover key trends and challenges. Watch this video to discover the survey’s key findings, and download the full MMIT Patient Access Report: https://ow.ly/I2iR50Tqrc1. #Pipeline2Patient #FollowNorstella
Norstella on LinkedIn: #pipeline2patient #follownorstella
linkedin.com
-
The future of patient care hinges not just on innovation but on how we bring treatments to market. With so many different stakeholders in the mix (payers, patients and policy makers, etc.) and the increase in launches of highly specialized treatments – such as personalized medicines or rare disease – the traditional go-to-market models for pharmaceutical products must also evolve significantly for this new world we live in. I’ll be joining a panel today at BioNJ’s C-Suite Summit on: Continued Evolutions in Go-To-Market Models to include Patient Services. This is a relevant and much needed discussion on how we can build new strategies with a clear goal in mind: patient access. The patient journey, and the needs of patients and their care partners are complex, and as our industry adapts, we’re finding new ways to streamline services, break down barriers, and drive impactful outcomes. Rohan Jain, Gina Murdoch, MBA, Haripriya Jain Christine Ann Miller #BioNJ #LifeSciences #PatientCare #GoToMarket #HealthcareInnovation https://lnkd.in/eFBRE_Yi
-
Just off the stage! Tabitha Henderson wrapped up her insightful panel discussion on "The Road to Specialty Pharmacy Network Selection" at #Asembia24. Huge thanks to her fellow panelists from Maxor Specialty Pharma, Orsini Specialty Pharmacy, and Harmony Biosciences for their invaluable observations. A few key takeaways from their panel include: - Strategic Alliances: The importance of building robust partnerships in specialty pharmacy to enhance patient access and adherence. - Innovative Solutions: Leveraging technology to streamline processes and improve patient outcomes. - Patient-Centric Approaches: Tailoring services to meet the unique needs of patients, ensuring they receive the right medication at the right time.
-
As part of a recent Reuters Events webinar, Ana Marija Gjurovic, MD, Global Head of Patient Engagement at AstraZeneca, highlighted a significant shift from pharma's traditional focus on healthcare professionals to actively involving patients. For more on this topic, read our article 'Empowering Patients: Transforming Drug Development through Engagement' here: https://lnkd.in/eijXA3DX #PatientCenteredCare #PharmaInnovation #CollaborativeHealthcare #PatientFirst
-
The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/4c6NdnB Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!
Pharma has long been guilty of putting profit before people, but that's beginning to change. While there's still a long road ahead, patient-engagement efforts are steadily improving.
1.reutersevents.com
-
The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/3AcWBsj Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!
Pharma has long been guilty of putting profit before people, but that's beginning to change. While there's still a long road ahead, patient-engagement efforts are steadily improving.
1.reutersevents.com
